JP2011132141A - Activated carrier for producing immobilized protein - Google Patents

Abstract

<P>PROBLEM TO BE SOLVED: To provide a technique of immobilizing a target protein by a covalent bond while controlling its orientation without altering the sequence thereof, and an activated carrier for immobilizing a protein using the technique. <P>SOLUTION: The activated carrier for producing an immobilized protein includes an intermediary protein and a carrier for immobilizing a target protein via the intermediary protein, which intermediary protein is free of lysine and cysteine and binds to the carrier by a covalent bond via either the carboxy terminal or the amino terminal thereof, with a carboxy group present on a side chain of an aspartic acid residue or of a glutamic acid residue or a carboxy group present on the carboxy terminal each constituting the intermediary protein, converted to a succinimide group. <P>COPYRIGHT: (C)2011,JPO&INPIT

Description

  The present invention relates to a protein characterized in that the target protein is covalently immobilized on a carrier via a mediator protein, and the related technical fields include a wide range of technical fields related to the immobilized protein, For example, protein orientation control immobilization, affinity analysis, affinity separation, chromatography carrier, immunoaffinity carrier, protein sensor, protein array, protein chip, microtus, antibody array, protein removal method, component test, clinical test, Etc. are included.

Applications Proteins are composed of a chain of amino acids, but usually form specific steric structures to express their functions, such as specific recognition and binding functions and catalytic functions that cannot be achieved with other macromolecules. . As means for utilizing such protein functions widely, binding (immobilization) to an insoluble substrate called a carrier, beads, fibers, membranes or soluble polymers is performed. Immobilized proteins are being used in a wide range of fields such as substance separation such as chromatography, biosensors, reactors, removal agents, and virus separation.

  For example, affinity chromatography is often used as a means for purifying or removing a specific protein. In affinity chromatography, a protein having affinity for a target substance (referred to as a ligand or a ligand protein) is immobilized on an insoluble carrier, and the target substance is specifically bound to the ligand to thereby bind the target substance. After separation from contaminants, purification can be performed by releasing and eluting from the ligand under appropriate conditions.

  For example, since a specific virus can be bound to an antibody by immobilizing an antibody against the specific virus on a filter or mask, it can be used as a virus removal filter or mask.

  Thus, it is obvious that a wide range of uses can be opened by immobilizing a protein having a function according to the purpose in combination with an appropriate carrier, and this expands the use expansion by immobilizing the protein. It is the driving force of that.

Immobilization technology It is obvious to those skilled in the art that the method of immobilizing a target protein on a carrier can be broadly divided into physical adsorption and chemical bonding depending on the form of the immobilization reaction. In addition, chemical bonds can also be classified into reversible bonds such as ionic bonds and irreversible bonds such as covalent bonds. Immobilization by physical adsorption or reversible chemical bonds is a mild and Although it is simple, the environmental conditions under which the immobilized protein is used often cannot cope with changes in the pH, salt concentration, temperature, etc. of the solution, and its use is very limited. When aiming at a wide range of applications, it may be desirable to use covalent bonding.

  In the case of carrying out protein immobilization by covalent bond, an amino group or carboxyl group at the end of the protein capable of reacting with the functional group by introducing a functional group for immobilization reaction on the surface of the carrier substrate, or Immobilization is usually performed by reaction with SH groups, amino groups, carboxyl groups and the like of protein side chains. In some cases, a covalent bond is formed between a functional group of a carrier substrate and a functional group of a protein side chain through a suitable spacer using a crosslinking reagent (crosslinker).

  When performing protein immobilization by covalent bond, the site (amino acid residue number, etc.) used for immobilization is specified according to the immobilization status from the viewpoint of the protein to be immobilized (site specific) It can be divided into categories when it cannot be identified as (fixed) (random fixed). Among these, when the protein is immobilized at one position on the end side of the protein, it is called orientation controlled immobilization because the orientation of the immobilized protein is aligned.

  In this way, protein immobilization techniques are extremely diverse, but when evaluated from the viewpoint of quality, such as the function, performance, and stability of the prepared immobilized enzyme, the ideal immobilization form is covalent bonding. It is obvious that an immobilized protein in a controlled orientation form is desirable.

  However, since a protein is a chain of amino acid residues composed of at most 20 types of amino acid residues, in order to produce an immobilized immobilized protein in a desired form, Various restrictions must be added to the amino acid sequence. For example, when using the SH group of a cysteine residue as a functional group for binding and performing orientation control immobilization on the terminal side of the protein, all cysteine residues in the protein are retained while retaining the function of the target protein. Substitution with other amino acid residues and introduction of cysteine residues responsible for binding to the terminal side have been carried out.

  By controlling the orientation and immobilizing, the function of the target protein is exerted to the maximum extent. The inventors have completely maintained the original function by immobilizing and controlling the dihydrofolate reductase. It is clear from the results (see Non-Patent Documents 1 and 2) and the results of immobilizing antibody molecules by various immobilization methods. By the way, when an antibody molecule is immobilized by covalent bond, it is impossible in principle to arrange the binding mode of the antibody molecule on the surface of the carrier. In extreme cases, it is indispensable for the substance recognition ability of the antibody molecule. Many documents indicate that immobilization occurs in a form where the site cannot be used, or that binding occurs in a form that greatly affects substance recognition ability. That is, the orientation of the immobilized antibody by covalent bond is an immobilized antibody in a completely heterogeneous form as a molecule, and the function of the antibody molecule, that is, the binding to the antigen by such heterogeneous immobilization. It has been reported that the ability decreases due to denaturation of antibody molecules, disordered orientation, chemical modification, and the like (see Non-Patent Documents 3 to 5).

  Furthermore, in using the immobilized protein, it is necessary to perform a so-called mask reaction in order to inactivate the introduced functional group for causing the surface of the carrier base material to perform the immobilization reaction. The protein to be converted is required to be insensitive to the mask reaction used.

  The present inventors have developed a protein immobilization reaction via cyanocysteine in order to ensure the binding at one end of the protein sequence, and not only the reaction but also the mask reaction of the functional group Are developing general forms of proteins that are also insensitive (see Patent Documents 1-6). In order to control the orientation and immobilize with a covalent bond, the protein sequence to be immobilized or the type of amino acid constituting it is greatly limited.

  As mentioned above, because immobilized proteins can be used in a wide range of applications, it is very difficult to covalently immobilize naturally-derived proteins by controlling the orientation using conventional techniques. Therefore, a new problem to be solved has arisen.

  That is, the development of a method for controlling the orientation and immobilizing with a covalent bond without modifying the sequence of the naturally derived protein. In particular, since antibody proteins are widely used as immobilized proteins, there is a need for technological development in order to control the orientation and immobilize them by covalent bonds without impairing the function of the antibody molecules.

Antibody molecule orientation control immobilization Antibodies are not limited to use as antibody drugs, but each molecular species recognizes and binds to a specific substance in a very specific manner, so various analyzes including diagnosis It can be used as a carrier for separation and purification by using the antibody itself as an affinity ligand. When antibodies are used for various analyzes and separations, it is convenient to use a form in which antibody molecules are immobilized on an insoluble substrate or carrier, that is, a form of an immobilized antibody. For example, a simple immunoassay system can be constructed by immobilizing antibody molecules on a 96-well immunoplate by so-called physical adsorption. In addition, a functional group is introduced on the surface of an insoluble carrier substrate and is immobilized in a form in which it is chemically bonded to the amino acid side chain of the antibody. However, when the antibody is immobilized in such a form, it is impossible in principle to arrange the binding mode of the antibody molecule on the surface of the carrier. May cause immobilization in a form in which essential sites cannot be used, which may greatly affect substance recognition ability. Considering this from the viewpoint of the orientation of the immobilized antibody, it must be said that it is an immobilized antibody in a completely heterogeneous form as a molecule. It has been reported that the function of an antibody molecule, that is, the ability to bind to an antigen, decreases due to such heterogeneous immobilization due to denaturation, disordered orientation, chemical modification, etc. of the antibody molecule (Non-patent Document 3). ~ 5). Therefore, it is desired to produce a more homogeneous immobilized antibody.

  In order to solve this problem, it has been carried out to control and fix the orientation of antibody molecules. In order to improve the orientation of antibody molecules on the carrier surface, it has been devised to use an antibody binding protein called protein A or protein G. These antibody-binding proteins are proteins that specifically bind to a site called an Fc domain that is different from the antigen recognition site. If these antibody-binding proteins can be immobilized on the carrier surface by controlling the orientation, the antibody molecules themselves can be immobilized by controlling the orientation via these immobilized antibody-binding proteins. It becomes. The schematic diagram 1 shown in FIG. 1 is a conceptual diagram showing this more generally.

  To express this in a more general way, in the immobilization of proteins for the purpose of orientation control immobilization, a small protein (ligand protein) that specifically binds to the target protein is used as an intervening protein in advance on the carrier surface. When the target protein is bound to the intervening protein by controlling and immobilizing, the orientation of the intervening protein itself is controlled, and the binding of the intervening protein and the target protein is bound by a fixed structure, so the orientation is fixed. The result is that the orientation of the target protein is determined by binding to the protein. At this time, if the site to which the intervening protein binds is a site that does not impair the functional expression of the protein intended for immobilization, immobilization of the target protein in such a form will ensure that the target protein is oriented. Thus, immobilization in a form that can guarantee a functionally uniform function can be realized.

  Covalent immobilization via intervening proteins in an uncontrolled manner has been proposed around 1978. DM Gersten and JJ Marchalonis mixed protein A and immunoglobulin G immobilized on Sepharose 4B with random covalent bonds, combined, and then treated with dimethyl suberimidate, a bivalent reagent. It shows that a cross-linking reaction was performed between protein A and immunoglobulin G, and both were bound by a covalent bond (see Non-Patent Document 6).

  However, there is no description that the function of immunoglobulin G bound by the cross-linking reaction was maintained, and to date, the immobilized antibody produced by such cross-linking is practical. There are no reports. This means that the reagent used for the cross-linking reaction mainly reacts with the amino group on the side chain of the lysine residue of the protein, and the cross-linking occurs between the side chain of protein A and immunoglobulin G. Only in some cases, cross-linking within the molecule or reaction on one side (so-called mere chemical modification) occurs, the function of the immobilized antibody itself is greatly lost, and the antibody molecule is immobilized via protein A. Even if it succeeds in itself, it is considered that it is because it is difficult to control the reaction into a form that can be used as an immobilized antibody (schematic diagram 2 shown in FIG. 2).

  The superiority of immobilization via intervening proteins in a controlled orientation has been proposed by around 1996. For example, R. Polzius et al. Immobilized protein G by immobilizing protein G by immobilizing protein G by physical adsorption, various chemical couplings, orientation control immobilization via biotin-avidin, and the like. By immobilizing immunoglobulins non-covalently, the function is maintained, and when immunoglobulin G is immobilized through protein G with orientation-controlled immobilization, the antibody functions to its full potential. It is shown that the orientation control immobilization is desirable (see Non-Patent Document 7).

  However, even if the intervening protein such as protein A or protein G is immobilized by controlling the orientation by covalent bond, when the intervening protein and the target protein are non-covalently bound, Since the target protein is released from the immobilized substrate due to changes in pH, salt concentration, etc., its use is greatly limited. For example, in an immobilized antibody in which a fluorescently labeled immunoglobulin G is bound to a carrier in which protein A is orientation-controlled under neutral conditions, by gradually coexisting with a high concentration of fluorescent unlabeled immunoglobulin G, the gradually labeled fluorescently labeled immunoglobulin G is used. Globulin G is released. Also, almost all immunoglobulin G is liberated only by adjusting the pH to 3 to 2.

JP 2008-115151 A JP 2008-115152 A JP 2008-115153 A JP 2008-266219 A JP 2008-266221 A JP 2008-280259 A

M Iwakura et al., J. Biochem. 119, 414-420 Masahiro Iwakura et al., Protein engineer., 14, 583-589. M. Nisnevitch et al., J. Biochem. Biophys. Methods, vol. 49, pp. 467-480 (2001) R. Danczyk et al. Biotechnol. Bioeng. Vol.84, pp.215-223 (2003) Yongwong Jung et al., Analytical Biochemistry, vol. 374, pp99-105 (2008) D.M.Gersten et al. J. Immunol.Methods 24 (1978), pp. 305-309. R. Polzius et al., Biosens. Bioelectron. 11 (1996), pp. 503-514.

  When considering the use of an immobilized protein, it is the most desirable form that the function of the protein to be immobilized is bound to the carrier by a covalent bond without losing the previous function. In order to achieve this object, as described above, it is a reliable method to fix the protein to be immobilized by covalent bonding with the orientation aligned through a site that does not impair the function. However, as described above, it is difficult to immobilize by controlling the orientation without altering the sequence of the protein intended for immobilization. Further, in the production of an array or the like, it takes a lot of labor and cost to convert the sequence of many proteins for immobilization.

  The present invention provides a technique for controlling and immobilizing a covalent bond without modifying the target protein sequence, and further provides an activated carrier for immobilizing an immobilized protein using the technique. Objective.

  In order to solve the above problems, the present inventors have already covalently bound a protein containing no lysine and cysteine, which has been invented by the present inventors, at either the amino- or carboxy-terminal side. Immobilized protein (this is referred to as an intervening protein) immobilized on an immobilization substrate by the above-mentioned method (referred to as JP 2008-115151, JP 2008-115152, JP 2008-115153, JP 2008-266219, 2008-266221, 2008-280259), and the interstitial protein is a protein that is specifically immobilized at a site other than the functional expression site. When it can be strongly bound by protein interaction, the carboxyl group on the side chain of the aspartic acid or glutamic acid residue in the intervening protein is specifically condensed with the amino group by the carbodiimide method. When activated and bound to the target protein, the protein structure fluctuates, and only the amino group of the lysine residue at or near the binding site of both proteins binds preferentially In addition, since the amino acid other than the amino acid residue involved in the binding does not change at all in the target protein, the target protein can be formed in the formation of a covalent bond between the intervening protein and the target protein. The idea of being able to bind by a covalent bond (amide bond) while maintaining the function of was obtained.

  Furthermore, it is confirmed that the idea is correct by modifying the amino acid sequence of protein A or protein G protein that specifically binds to the Fc domain of immunoglobulin G protein, which has already been invented by the present inventors. That the immunoglobulin G protein can be orientation-controlled and immobilized, that is, the object of the present invention can be achieved, by using an immobilized protein that is covalently bonded and orientation-controlled and immobilized in a form that does not contain any of I found it.

  Since living organisms have proteins that specifically bind to specific proteins, it is also known that proteins that specifically bind to the target protein can be arbitrarily created by protein engineering technology or phage display technology. . Furthermore, the amino acid residues that constitute such a binding protein not to contain any lysine or cysteine residues so as not to lose the function of any protein, as we have already shown Is also known (Japanese Patent Laid-Open No. 2008-115151, Japanese Patent Laid-Open No. 2008-115152, Japanese Patent Laid-Open No. 2008-115153, Japanese Patent Laid-Open No. 2008-266219, Japanese Patent Laid-Open No. 2008-266221, Japanese Patent Laid-Open No. 2008-266221, 2008-280259). Therefore, it is possible for those skilled in the art to create a protein that specifically binds to the target protein and a protein that does not contain any lysine and cysteine residues by using known techniques. Furthermore, creation of an immobilized protein in which the protein thus created is immobilized by covalent bond and orientation control can also be achieved by known techniques. Therefore, the protein of the present invention can be generalized because an immobilized protein in which orientation control is immobilized using a protein that does not contain any lysine or cysteine residue, which is a major component of the present invention, as an intervening protein can be created. The idea was reached and the present invention was completed.

  As shown in the schematic diagram 1 shown in FIG. 1, the immobilized protein of the present invention is composed of a carrier, an intervening protein, and a target protein, and the target protein is in a form in which orientation is controlled via the intervening protein. It is covalently bonded to the carrier.

  The structure of the immobilized protein itself in such a form can be easily devised by those skilled in the art. However, the major feature of the present invention is that the amino acid residues constituting the immobilized protein are intervening. The amino acid residues other than the amino acid residues involved in the covalent bond with the protein are exactly the same as before immobilization, that is, they are not subjected to chemical modification in the immobilization treatment of the target protein.

  Prior to the present invention, when the immobilized protein having the configuration shown in FIG. 1 was prepared, the intervening protein and the target protein were bound in advance, and then treated with a cross-linking reagent such as a bivalent reagent, thereby covalently binding. The connection was made by However, treatment with a crosslinking reagent or the like in the state where the intervening protein and the target protein coexist can cause intramolecular cross-linking other than the target cross-linking or simple chemical modification of amino acid residues. That is, an immobilized protein such as that represented by the schematic diagram 2 shown in FIG. 2 was generated, and it was impossible to reliably create the immobilized protein of the present invention.

  The present invention provides a method for reliably generating the protein shown in the schematic diagram 1, and as a result, for the first time, the immobilized protein shown in the schematic diagram 1 that could not be created before the present invention was created. . Therefore, the immobilized protein of the present invention shown in the schematic diagram 1 is a completely new substance.

That is, the present invention is as follows.
[1] An activated carrier for preparing an immobilized protein comprising an intervening protein and a carrier for immobilizing a target protein via the intervening protein, wherein the intervening protein not containing lysine and cysteine An activated carrier for preparing an immobilized protein, which is bound by a covalent bond via a carboxy terminus, and the carboxyl group of the side chain of the aspartic acid residue or glutamic acid residue of the protein is succinimidated.
[2] An activated carrier for preparing an immobilized protein comprising an intervening protein and a carrier for immobilizing a target protein via the intervening protein, wherein the intervening protein not containing lysine and cysteine is an amino acid of the protein An activated carrier for preparing an immobilized protein, which is covalently bonded via a terminal, and the carboxyl group of the side chain of the aspartic acid residue or glutamic acid residue of the protein is succinimidated.
[3] The activated carrier for producing an immobilized protein according to [1] or [2], wherein the carrier is an insoluble carrier.
[4] The activated carrier for preparing an immobilized protein according to any one of [1] to [3], wherein the intervening protein not containing lysine and cysteine is a protein having an antibody binding function.
[5] Activation for production of immobilized protein according to [4], wherein the protein not containing lysine and cysteine is a modified protein of an antibody binding domain derived from a protein selected from the group consisting of protein A, protein G and protein L Carrier.

  By utilizing the intervening protein, the orientation is controlled and the excess function can prevent side reactions, and an immobilized protein with high homogeneity as a substance can be produced with high efficiency. The immobilized protein thus obtained can be expected to be used in many fields including sensing materials and separation materials for affinity purification.

It is a figure which shows the state which the target protein comprised with the support | carrier, the intervening protein, and the target protein, and the target protein couple | bonded with the support | carrier in the form by which orientation was controlled through the intervening protein. It is a figure which shows the state couple | bonded by the covalent bond by couple | bonding intervening protein and the target protein previously, and then processing by cross-linking reagents, such as a bivalent reagent.

Hereinafter, the present invention will be described in detail.
Antibody Orientation Control Immobilization The immobilized protein of the present invention is not limited, and includes any protein having a specific function. Among them, immunoglobulin G having binding ability, particularly monoclonal antibody can be mentioned.

  Hereinafter, the content of the present invention, its usage and effects will be described in more detail with respect to the immobilized antibody and the immobilized monoclonal antibody.

Component [How to obtain antibodies and monoclonal antibodies]
Since an antibody is a protein produced by an organism having an immune system and has a function of specifically binding to an antigen, the substance recognition function of the antibody is widely used artificially. Further, as an antibody capable of recognizing and binding one antigen, many protein molecules are isolated even from various organisms or the same species. Among them, antibodies with high utility value are commercially available, and many antibodies that can specifically bind to a certain antigen are commercially available. Even if it is not available, those skilled in the art can produce the target antibody by immunizing the immunized animal with the target antigen. Accordingly, when preparing an immobilized antibody, there is almost no limitation on the acquisition of the antibody, and it can be obtained. Therefore, it is obvious that the present invention is not limited by the acquisition of the antibody protein.

  Monoclonal antibodies differ greatly from the fact that antibody proteins produced by immunized animals are derived from multiple antibody-producing cells, and heterogeneous in antigen recognition such as epitopes, and are derived from single antibody-producing cells. There is one feature that the gene sequence to be encoded is one kind, and the protein sequence is also a uniform antibody. Monoclonal antibodies can also be obtained as commercial products or produced by those skilled in the art.

  The present invention provides a technique that enables a commercially available antibody protein to be used by controlling its orientation by covalent bonding and immobilizing it on a carrier without any special treatment. In the immobilized antibody produced by the present invention, amino acid residues other than the side chain amino group or amino terminal amino group of the lysine residue involved in the immobilization reaction can be chemically treated by immobilization treatment. It has the characteristic that it has not undergone any changes. Therefore, when a residue involved in immobilization does not participate in the functional expression of the antibody protein, it is guaranteed that the function of the antibody protein is completely maintained by immobilization.

[Protein having binding ability to antibody molecule as intervening protein]
In the present invention, the protein used for orientation control immobilization by covalent bond with an antibody as an intervening protein has already been invented by the present inventors and does not contain any lysine and cysteine residues and has an amino terminal or carboxy group. Examples include immobilized proteins that are covalently bonded to a carrier at one end (Japanese Patent Laid-Open No. 2008-115151, Japanese Patent Laid-Open No. 2008-115152, Japanese Patent Laid-Open No. 2008-115153, Japanese Patent Laid-Open No. 2008-266219, JP 2008-266221 A, JP 2008-280259 A).

  Examples of proteins having binding ability to antibody molecules include protein A derived from Staphylococcus aureus (described in A. Forsgren and J. Sjoquist, J. Immunol. (1966) 97, 822-827.), Streptococus sp. Group C / G Protein G derived from EP (described in EP0131142A2 (1983)), Protein L derived from Preptostreptococcus magnus (described in US5965390 (1992)), Protein H derived from group A Streptococcus (described in US5180810 (1993)), Protein D derived from Haemophilus influenzae (Described in US6025484 (1990)), Streptococcus AP4-derived protein Arp (Protein Arp 4) (described in US5210183 (1987)), group C Streptococcus-derived Streptococcal FcRc (described in US4900660 (1985)), group A streptococcus, Type II Protein derived from strain (described in US5556944 (1991)), protein derived from Human Colonic Mucosal Epithelial Cell (described in US6271362 (1994)), protein derived from Staphylococcus aureu, strain 8325-4 (US6548639 (1997) Wherein) wherein) and the like are known in Pseudomonas maltophilia derived protein (US5245016 (1991). In addition, regarding these proteins, in many cases, it has been clarified that a fragmented protein has a binding ability to an antibody molecule even in a fragmented protein. By replacing all lysine residues and cysteine residues present in the binding protein sequence with other 18 kinds of amino acid residues based on all sequences while maintaining the antibody binding ability, It is already known in the inventions by the present inventors that an intervening protein to be used in (JP 2008-115151, JP 2008-115152, JP 2008-115153, JP 2008-266219, JP 2008-266221, JP 2008-280259).

  Among the antibody-binding proteins described above, protein A and protein G recognize a domain completely different from the antigen recognition and binding site called Fc domain of antibody protein immunoglobulin G, and bind noncovalently. In addition, the Fc domain includes a plurality of lysine residues, which are exposed on the protein surface in the protein structure, and have a structure in which the amino group on the side chain of the lysine residue can be used for the binding reaction.

  In the examples of the present invention, as an intervening protein, a solidified protein in which a modified protein A domain or modified protein G domain containing no lysine residue and cysteine residue is bound to each other via a glycine linker is used as a carrier. However, it is obvious that the present invention is not limited to the modified protein A domain or the modified protein G domain.

  As a protein used for immobilizing an intervening protein on a carrier, a protein having a sequence represented by the following general formula (1), which has already been invented by the present inventors, is expressed and purified in a biological host such as Escherichia coli. Can be used.

General formula (1) R1-R2-R3-R4-R5
[In the formula, the sequence represents a sequence from the amino terminal side to the carboxy terminal side,
The sequence of the R1 portion is the sequence of the protein to be immobilized, and is a sequence characterized by not containing lysine residues and cysteine residues;
The sequence of the R2 moiety may not be present, and if present is a spacer sequence composed of amino acid residues other than lysine and cysteine residues;
The sequence of the R3 portion is a sequence composed of two amino acids represented by cysteine-X (X is an amino acid residue other than lysine or cysteine);
The R4 portion sequence may not be present, and if present, is a sequence that does not include lysine residues and cysteine residues, and is a protein comprising an amino acid sequence represented by the general formula R1-R2-R3-R4-R5 A sequence characterized in that it contains acidic amino acid residues that can bring the entire isoelectric point to the acidic side; and the sequence of the R5 moiety is an affinity tag sequence for purifying the protein]

  This protein is bound to a carrier having an amino group as a functional group by an amide bond at one end by an immobilization reaction via cyanocysteine, and then treated with acetic anhydride, so that an amino group that does not participate in the binding in the carrier. To mask unreacted amino groups by acetylation. As a result, an immobilized protein carrier having no free amino group including the amino terminus of the intervening protein can be produced. The amino terminus of the intervening protein is also acetylated by the amino group mask reaction. In the case of the modified protein A domain or the modified protein G domain, even if the amino terminus was acetylated by a mask reaction, no effect on the antibody binding function was observed.

[Covalent binding of antibody protein via intervening protein]
After immobilization at one position on the carboxy terminal side of the modified (mutated) protein A domain or modified protein G domain containing no lysine residue and cysteine residue, an immobilized protein subjected to mask reaction was used as carbodiimide. By treatment with succinimide, the side chain carboxyl groups of the immobilized modified protein A domain or modified protein G domain of the aspartic acid and glutamic acid residues can be succinidized. The succinimidated carboxyl group has strong reactivity with the amino group, and forms an amide bond by the reaction. Therefore, by mixing the immobilization carrier succinimidized with the antibody protein, the amino group of the lysine residue or the amino group at the amino terminus in the antibody molecule becomes the aspartic acid residue of the modified protein A domain or the modified protein G domain. It binds covalently by reacting with a succinylated carboxyl group on the side chain of the glutamic acid residue to form an amide bond. This reaction is preferentially formed between very limited amino acid side chains because the modified protein A domain or the modified protein G domain specifically binds to the Fc domain of the antibody molecule. This is clearly shown in the Examples, and when the modified protein A domain that lost the antibody binding ability was used, the binding reaction with the antibody hardly occurred, and the carrier and antibody protein on which the intervening protein was immobilized This can be achieved by avoiding non-specific binding by washing as soon as possible after mixing. After the immobilization reaction, the succinimidated carboxyl group in the intervening protein can be masked by treatment with ethanolamine or the like.

  In the present invention, after interstitial protein is succinimidated, an antibody protein is added to cause an immobilization reaction. In this immobilization reaction, the antibody protein has a ligation other than a lysine residue that has formed an amide bond. Side chain amino acid residues are not chemically altered at all.

  By this reaction, the immobilized antibody protein is immobilized in a form in which the modified protein A domain, which is an intervening protein, and the Fc domain of the antibody are covalently bonded by an amide bond, that is, in a controlled orientation. Its own antigen recognition / binding function is completely maintained. In addition, since the intervening protein itself is immobilized in a covalent bond and controlled orientation, an immobilized protein in which the antibody protein is immobilized in a covalent bond and controlled orientation was formed. It will be. The fact that the immobilized protein in such a form is a completely new substance is that it is difficult to control the immobilization reaction even if the conventional method is used, and it is difficult to prepare it before the present invention. It is self-evident when considering what was possible. Accordingly, the present invention not only provides a method for producing a protein having a fixed shape whose orientation is controlled by a covalent bond, but also provides a completely new substance as a substance. It is obvious that

[Carrier for immobilizing intervening protein]
The carrier used in the present invention may be any carrier as long as it is larger than the protein molecule, and may be either soluble or insoluble.

  The intervening protein can be immobilized on the carrier by covalent bonding of the carboxy terminus of the intervening protein to the surface of the carrier via an amide bond. In addition, the amino terminus of the intervening protein can be immobilized on the surface of the carrier by covalent bonding. That is, the intervening protein can be immobilized on the surface of the carrier by a covalent bond via the α-amino group of the amino acid.

An amino group (R—NH ₂ ) must be introduced as a functional group as a carrier for immobilizing the intervening protein by controlling the orientation on the carboxy terminal side. Examples of the soluble carrier include amino group polymers such as polyallylamine and polylysine as amino group polymers, and copolymers thereof.

  As the insoluble carrier, a carrier that can be used for chromatography can be used. In addition, particulate carriers, monolith type carriers, membrane carriers, fibrous carriers, holofiber carriers, plate-like or sheet-like substrates, magnetic beads, and the like that can immobilize proteins, Both are included. “Immobilization carrier” includes “immobilization substrate”. As a material for forming the carrier having such a shape, any material having a functional group for orientation-immobilizing and immobilizing the intervening protein on the surface may be used, such as polyethylene, polypropylene, polystyrene, polymethacrylate, Plastics such as polyvinyl alcohol, hydrogels, agarose, dextran, cellulose, natural materials such as chitosan, inorganic materials such as silica, glass, ceramics, gold, alumina, silver, etc. It can be used in a wide range of metal materials. Furthermore, a microchannel can also be used as a carrier. Here, the microchannel refers to a microchip or the like in which a micron-order high-precision channel is formed on a flow channel cell or a glass substrate, and the protein may be immobilized on the glass in the channel.

  Here, as a commercially available carrier into which a functional group is introduced, amino-cellulofine (sold by Seikagaku), AF-aminotoyopearl (sold by TOSOH), EAH-sepharose 4B and lysine-sepharose 4B (Amersham Bioscience) Porous 20NH (sold at Boehringer Mannheim), CNBr activated Sepharose FF, NHS activated Sepharose FF, etc. Further, those skilled in the art can introduce a functional group such as an amino group into a silica carrier, glass beads, or glass flat plate using a silane compound having a primary amino group (for example, 3-aminopropylmethoxysilane). If you can.

  Some of these activation methods use strong alkaline reagents or powerful drugs, but this is used when activating on the solid or semi-solid side alone. In this case, no problem occurs because the protein is introduced.

  The present invention also includes a carrier in which an intervening protein not containing lysine and cysteine is bound by a covalent bond, and a carrier in which the carboxyl group of the side chain of the aspartic acid or glutamic acid residue of the intervening protein is succinimidated. Including. In the present invention, the carrier is referred to as an activated carrier for producing an immobilized protein, and the target protein can be immobilized on the activated carrier in a state in which the orientation of the target protein is controlled.

Generality and generality of the present invention As described above, the present invention has been described in detail by taking an example of an immobilized protein in which an antibody molecule is immobilized. As described above, the combination of an immobilized target protein and an intervening protein is Since it is obvious that a person skilled in the art can create an intervening protein that is infinite and does not contain lysine and cysteine, the immobilized protein of the present invention is not limited by the target protein. Proteins are also applicable. For example, a group of small proteins called Affibody (registered trademark) Molecule has been developed and sold as target proteins, and it is known that each small protein specifically binds only to a certain target protein. Affibody (registered trademark) Molecule was created by modifying the sequence of the protein derived from the B domain of protein A derived from Staphylococcus aureus, but the sequence contains a lysine residue. The lysine residue portion can be converted to other amino acids while maintaining the function of the protein, as can be achieved by the parties, as already shown by the inventors using the A domain of protein A derived from Staphylococcus aureus. (JP 2008-115151, JP 2008-115152, 2008-115153, 2008-266219, 2008-266221, 2008-280259). Therefore, it is clear that the technique of the present invention is not limited by the target protein, and generality is maintained.

  The present invention will be specifically described by the following examples, but the present invention is not limited to these examples.

1. Materials Commercially available products were used as human polyclonal antibodies. The anti-IL8 human monoclonal antibody used was cultured from the ATCCCRL-12445 strain as CHO cells and purified from the culture supernatant. As human monoclonal antibodies, Avastin, Herceptin, Rituxan, those sold as pharmaceuticals were used.

  For the modified protein A, the protein shown in SEQ ID NO: 1 is used as the ligand protein, and the protein shown in SEQ ID NO: 2 is used as the modified protein G, and this is immobilized by orientation control immobilization reaction via cyanocysteine. What was obtained by forming was used. As a result of the immobilization by the ligand immobilization reaction, the intervening sequence is a modified protein A domain (SEQ ID NO: 3) that does not contain any lysine residues and cysteine residues, or a modification that does not contain any lysine residues and cysteine residues. The protein G domain (SEQ ID NO: 4) plays the role of intervening protein in a form immobilized on the carrier substrate via the C-terminal side.

  The carrier substrate has an amino group on the surface of the carrier substrate. The silica monolith substrate was provided by courtesy of Kyoto Monotech Co., and the silica bead carrier was courtesy of AGC S-Tech Co., Ltd. It has been provided. Aminocellulofine and AF-aminotoyopearl were used as they were on the market.

  Immobilization of a modified protein A domain or protein G that does not contain any lysine residue and cysteine residue on a carrier substrate having an amino group on the surface of the carrier substrate is a known method disclosed by the present inventors ( As described above, after the immobilization reaction, an excess amino group on the support surface was treated with acetic anhydride to perform a blocking treatment. The product thus obtained was used as a carrier into which an intervening protein was introduced.

2. Antibody Immobilization Reaction and Immobilization Efficiency Measurement Method About 0.1 mL of a carrier into which an intervening protein has been introduced is placed in a spin column, 10 mM borate buffer, pH 8.5, 0.4 mL is added, and 3000 rpm is 2 minutes. Centrifugation was performed, the buffer solution was passed through the column, and the column was washed with the carrier. The buffer eluted from the column was received in a 1.5 mL Eppendorf type centrifuge tube. The eluted buffer solution was discarded, the borate buffer solution was added again to the spin column, the centrifugation step was performed in the same manner, and this step was repeated three times to wash the carrier.

  Next, as activation of the carboxyl group of the modified protein A domain or the modified protein G domain immobilized on the carrier, 50 mM N-hyhydroxysuccinimide (hereinafter NHS) and 200 mM 1 ethyl- (3- A dimethylaminopropyl) carbodiimide (hereinafter, EDC) solution (hereinafter, NHS / EDC solution) was used. Add 0.4 mL of NHS / EDC solution to the spin column, perform centrifugation at 3000 rpm for 2 minutes, discard the eluted solution, repeat this operation twice, and then add 0.8 mL of NHS / EDC. The solution was added and the carrier was immersed. In this state, after standing at room temperature for 2 hours, the NHS / EDC solution was eluted and discarded at 3000 rpm for 2 minutes. The carrier thus obtained is referred to as an activated carrier.

  The antibody to be immobilized was dissolved in 10 mM borate buffer, pH 8.5 to a final concentration of 0.1 to 1.0 mg. The protein concentration was measured by the BCA method and determined as bovine serum albumin equivalent.

  0.4 mL of the antibody solution to be immobilized was added, and after the addition and stirring, the solution was quickly separated by centrifugation at 3000 rpm for 2 minutes (referred to as an adsorption step). This operation was performed twice (referred to as the amount of non-adsorbed protein).

  The separated solution was collected and the amount of protein in the solution was measured. To the carrier after centrifugation, 10 mM borate buffer, pH 8.5, 0.4 mL was added and stirred, and then the solution was quickly separated by centrifugation at 3000 rpm for 2 minutes. Called). The washing step was performed twice, and then 0.4 mL of the same buffer solution was added and stirred, and then allowed to stand overnight at room temperature to cause the antibody immobilization reaction.

  After completion of the reaction, the solution was separated by centrifugation at 3000 rpm for 2 minutes. The solution obtained by the washing step and the solution obtained by this operation were collected, and the amount of protein in the solution was measured.

  After the completion of the reaction, 0.1 M glycine buffer solution, pH 2.5, 0.4 mL was added to the support and stirred, and then the solution was quickly separated by centrifugation at 3000 rpm for 2 minutes (this operation was combined with washing step 2). Called). Washing step 2 was performed three times, the resulting solution was recovered, and the amount of protein in the solution was measured.

  After adding 1M ethanolamine hydrochloride, pH 8.5, 0.4 mL to the carrier obtained by this operation and stirring, the solution was quickly separated by centrifugation at 3000 rpm for 2 minutes (this operation was called blocking operation). Called). The blocking operation was performed twice, and then 0.4 mL of the same solution was added and stirred, and then allowed to stand overnight at room temperature to cause the antibody immobilization reaction. After completion of the reaction, the solution was separated by centrifugation at 3000 rpm for 2 minutes. The solution obtained by the washing step and the solution obtained by this operation were collected, and the amount of protein in the solution was measured (blocking step).

  By the above operation, the protein amount of each of the various solutions obtained is obtained, and the total amount of the antibody added to the carrier is obtained by obtaining non-adsorbed protein + washing step 1 + washing step 2 + blocking step (total amount of non-binding protein) as the total By subtracting from (total protein amount used in the adsorption step = protein concentration × 1.2 mL), the protein amount of the immobilized antibody was determined.

3. Results using monolithic carrier The course of using a carrier in which modified protein A or modified protein G is introduced into the monolithic carrier is first shown in detail.

  As an antibody to be immobilized, an anti-human IL8 human antibody was used.

Antibody concentration: 0.34 mg / mL
Total amount of applied antibody protein (hereinafter referred to as A): 0.34 mg × 0.8 mL = 0.272 mg
Total non-adsorbed protein:
Modified protein A carrier: 0 mg
Modified protein G carrier: 0 mg
Washing step 1 eluted protein:
Modified protein A carrier: 0.008 mg
Modified protein G carrier: 0.068 mg
Washing step 2 eluted protein:
Modified protein A carrier: 0.072 mg
Modified protein G carrier: 0.024 mg
Blocking process eluted protein:
Modified protein A carrier: 0 mg
Modified protein G carrier: 0 mg
Total amount of non-immobilized protein (hereinafter referred to as U)
Modified protein A carrier: 0.080 mg
Modified protein G carrier: 0.092 mg
Total amount of immobilized protein (hereinafter referred to as B)
Modified protein A carrier: 0.192 mg
Modified protein G carrier: 0.180 mg

As a result, the immobilization efficiency is
Immobilization efficiency = 100 × (total amount of immobilized protein (B)) / (total amount of applied antibody protein (A) −total amount of non-adsorbed protein (U))
Is calculated from
Immobilization efficiency (E = 100 × B / (A−U) calculation formula)
Modified protein A carrier: about 71%
Modified protein G carrier: about 66%
It was the result.

4). Results Using Other Carriers Various experiments were carried out in the same manner as described above, changing the combination of carrier substrate, intervening protein, and antibody. Measurement of the amount of antibody immobilized was carried out with 0.4 mL of the carrier on which the intervening protein was immobilized (as is in the case of a spin column) and the total amount of antibody protein to be applied was about 0.4 mg. Table 1 summarizes the results, and collectively shows the total amount (B) of the immobilized protein and the immobilization efficiency (E). In this measurement, the amount of immobilization of the intervening protein is not optimized, and the amount of immobilization is not measured. It is clear that the total amount of protein depends on the amount of intervening protein.

表１ 介在タンパク質をあらかじめ固定化した各種担体を用いた時の各種抗体タンパク質の固定化量と固定化効率のまとめ

Table 1 Summary of immobilization amount and immobilization efficiency of various antibody proteins when using various carriers in which intervening proteins are immobilized in advance

5. Recovery of antigen using immobilized antibody Using the spin column on which the human anti-IL8 human antibody obtained in 3 above is immobilized, a binding elution experiment was conducted using a commercially available human IL8 peptide. It was.

  Human IL8 peptide was dissolved in 0.1 M phosphate buffer, pH 7.4, to a final concentration of 0.1 mg. The protein concentration was measured by the BCA method and determined as bovine serum albumin equivalent.

  0.4 mL of peptide solution was added, and after the addition and stirring, the solution was quickly separated by centrifugation at 3000 rpm for 2 minutes (referred to as an adsorption step). This operation was performed twice. The separated solution was collected, and the amount of protein in the solution was measured (referred to as the amount of non-adsorbed peptide).

  To the carrier after centrifugation, 0.1 M phosphate buffer solution containing 0.5 M NaCl, pH 7.4, 0.4 mL was added and stirred, and then the solution was quickly separated by centrifugation at 3000 rpm for 2 minutes. (This operation is called a washing step). The washing process was performed 3 times. The separated solution was collected and the amount of protein in the solution was measured.

  Next, 0.1 M glycine buffer, pH 2.5, 0.4 mL was added and stirred, and then the solution was separated by centrifugation at 3000 rpm for 2 minutes (this operation is referred to as an elution step). The elution process was performed 3 times, and the resulting solution was recovered and the amount of protein in the solution was measured.

The total amount of peptide applied as a result: 0.1 mg × 0.8 mL = 0.08 mg
Total amount of non-adsorbed peptide: 0.002
Total amount of peptide eluted in washing process: 0 mg
Elution process total protein: 0.074mg
Adsorption efficiency = 100 × (total amount of applied peptide−total amount of non-adsorbed IL8 peptide) / total amount of applied IL8 peptide = about 98%
Elution recovery efficiency = 100 × elution step total protein / applied total peptide = approximately 93%
It was the result.

  The immobilized protein of the present invention has a wide range of technical fields related to the immobilized protein, such as protein orientation control immobilization, affinity analysis, affinity separation, chromatographic carrier, immunoaffinity carrier, protein sensor, protein array, protein chip, It can be used for microtuses, antibody arrays, protein removal methods, component tests, clinical tests, and the like.

1 Carrier (immobilized substrate)
2 Intervening protein 3 Immobilized protein (target protein)
4 Immobilization site (domain) of immobilized protein
5 Functional expression site (domain) of immobilized protein
6 Covalent bond 7 Binding / modification with cross-linking reagent

SEQ ID NOs: 1-4 synthesis

Claims (5)

  An activated carrier for preparing an immobilized protein comprising an intervening protein and a carrier for immobilizing a target protein via the intervening protein, wherein the intervening protein not containing lysine and cysteine has the carboxy terminus of the protein An activated carrier for preparing an immobilized protein, which is bound by a covalent bond, and the carboxyl group of the side chain of the aspartic acid residue or glutamic acid residue of the protein is succinimidated.   An activated carrier for preparing an immobilized protein comprising an intervening protein and a carrier for immobilizing the target protein via the intervening protein, wherein the intervening protein not containing lysine and cysteine is passed through the amino terminus of the protein. An activated carrier for preparing an immobilized protein, which is bound by a covalent bond, and the carboxyl group of the side chain of the aspartic acid or glutamic acid residue of the protein is succinimidated.   The activated carrier for preparing an immobilized protein according to claim 1 or 2, wherein the carrier is an insoluble carrier.   The activated carrier for preparing an immobilized protein according to any one of claims 1 to 3, wherein the intervening protein not containing lysine and cysteine is a protein having an antibody binding function.   The activated carrier for preparing an immobilized protein according to claim 4, wherein the protein not containing lysine and cysteine is a modified protein of an antibody binding domain derived from a protein selected from the group consisting of protein A, protein G and protein L.

Images